Treatment of Lyme borreliosis.
Borrelia burgdorferi sensu lato is the causative agent of Lyme borreliosis in humans. This inflammatory disease can affect the skin, the peripheral and central nervous system, the musculoskeletal and cardiovascular system and rarely the eyes. Early stages are directly associated with viable bacteria at the site of inflammation. The pathogen-host interaction is complex and has been elucidated only in part. B. burgdorferi is highly susceptible to antibiotic treatment and the majority of patients profit from this treatment. Some patients develop chronic persistent disease despite repeated antibiotics. Whether this is a sequel of pathogen persistence or a status of chronic auto-inflammation, auto-immunity or a form of fibromyalgia is highly debated. Since vaccination is not available, prevention of a tick bite or chemoprophylaxis is important. If the infection is manifest, then treatment strategies should target not only the pathogen by using antibiotics but also the chronic inflammation by using anti-inflammatory drugs.
Girschick
Hermann J
HJ
Paediatric Rheumatology, Immunology, Osteology and Infectious Diseases, Children's Hospital, University of Wuerzburg, Josef-Schneider-Str, 2, 97080 Wuerzburg, Germany. Hermann.Girschick@mail.uni-wuerzburg.de
Morbach
Henner
H
Tappe
Dennis
D
D000907:Antibodies, Bacterial / Q000627:therapeutic use; D025065:Borrelia burgdorferi; D054884:Host-Pathogen Interactions; D006801:Humans; D008193:Lyme Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D000907:Antibodies, Bacterial